SYNthesis Research

Integrated drug discovery - hit identification, lead generation and lead optimisation using medicinal chemistry, computational chemistry and in vitro biology. Through long-term strategic alliances we incorporate X-ray crystallography, ADME/tox, in vivo PK, and in vivo disease models. Experience across a wide range of disease areas, such as respiratory, oncology and CNS, and biological targets, e.g. kinases, GPCRs, PPIs, NHRs & epigenetics. Clients located in the USA, Europe and Australasia.

Organisation type
Mr Simon Bury
Global Head of Business Development 
Professor Andrew Wilks